Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 191 - 200 of 333

<< Previous | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | Next >>

Last updated: 20th February 2008

Patent No.: WO 095724
Expression of a hypersensitive response elicitor gene in combination with other transgenes in plants to improve growth, stress tolerance, disease or insect resistance.
Applicant: Wei Z-M, Derocher J (2001)
The present invention relates to methods of improving the effectiveness of transgenic plants, either by maximizing the benefit of transgenic trait in transgenic plants or overcoming deleterious effects on growth, stress tolerance, disease resistance, or insect resistance in transgenic plants expressing a transgenic trait. By applying a hypersensitive response elicitor protein or polypeptide to a transgenic plant expressing a transgene which confers a transgenic trait, or by prepg. a transgenic plant expressing both a transgene which confers a transgenic trait and a second transgene which confers hypersensitive response elicitor expression, it is possible to realize the max. benefit of the transgenic trait or overcome deleterious effects on growth, stress tolerance, disease or insect resistance, male sterility, modified flower color or biochem. modified plant products which result from or accompany expression of the transgene conferring the transgenic trait. The hypersensitive response elicitor protein can be applied to the plant or seed at a concn. greater than 0.5 nM by spraying, injection, dusting, immersion or leaf abrasion in water, aq. solns., slurries or powder.

Patent No.: WO 092309
Human antimicrobial peptide beta-defensin-3, its sequence, pharmaceutical compositions containing it, and use of compositions in preventing growth of bacteria or other microbes.
Applicant: McCray PB Jr., Tack B, Jia HP, Schutte BC (2001)
The invention provides a novel human antimicrobial peptide, designated beta-defensin-3 (HBD-3), and derivs. thereof. The invention also provides the amino acid sequence of the HBD-3 precursor (contains a signal peptide), and the sequences for two possible mature forms of HBD-3. The invention further provides a cDNA mol. encoding the said HBD-3, and an expression vector contg. said cDNA mol. Still further, the invention provides a pharmaceutical compn. contg. said HBD-3, which can be be administered topically, orally or parenterally, and can be used to inhibit or prevent the growth of bacteria or other microbes. Finally, the invention relates that the HBD-3 can be used alone, or in combination with other antimicrobial agents (such as inhibitors of protein synthesis, cell wall growth, cell membrane synthesis, or nucleic acid synthesis) to inhibit microbial growth and/or infection. In the example section, the invention: (1) looked at the tissue expression of HBD-3 mRNA; (2) presented the cDNA sequence of HBD-3 (GenBank AF217245), and (3) characterized the genomic organization of the HBD-3 gene.

Patent No.: WO 068085
A method for stimulation of defensin production.
Applicant: Fehlbaum P, Anderson M, Rao M, Zasloff M (2001)
The subject invention relates to a method for the stimulation of defensin prodn. in eukaryotic cells such as, for example, mammalian cells. The method comprises exposing the eukaryotic cells to a compn. comprising isoleucine or active isomers or analogs thereof. Furthermore, the invention includes said method for the prevention and treatment of infections and other various disease states and in the stimulation of the immune system. The invention also includes a method of stimulating the growth beneficial probiotic bacteria such as Lactobacilli, Bifidobacteria and Streptococci. The invention also includes a method for improving the general health, total wt. gain, rate of wt. gain, efficiency of feed conversion and/or redn. of elimination of carriage of pathogenic organisms in livestock. These benefits are known or are expected benefits of probiotic bacteria and therefore are also expected due to the probiotic effects described.

Patent No.: WO 064927
Expression of an antimicrobial peptide via the plastid genome to control phytopathogenic bacteria.
Applicant: Daniell H (2001)
This invention provides a novel method to confer disease resistance to plants. Plant plastids are transformed using a plastid vector which contains heterologous DNA sequences coding for a cytotoxic antimicrobial peptide. Transgenic plants are capable of fighting off phytopathogenic bacterial infection.

Patent No.: WO 062789
Sequence homologs of known human proteins and sequences encoding them.
Applicant: Ni J, Shi Y, Ebner R, Choi GH, Ruben SM (2001)
The present invention relates to novel human polypeptides and isolated nucleic acids contg. the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing the human polypeptides of the invention. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human polypeptides.

Patent No.: WO 055306
Protein and cDNA sequences of novel human defensin-like proteins.
Applicant: Rosen CA, Barash SC, Ruben SM (2001)
The present invention relates to novel polynucleotides and the polypeptides encoded by these polynucleotides, and the use of such proteins, which are defensin-like proteins, for diagnosing, treating, preventing disorders related to these novel peptides. More specifically, 1 isolated cDNA mol. is provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing novel human polynucleotides and/or polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compns. for inhibiting the prodn. and function of the polypeptides of the present invention.

Patent No.: WO 049702
Protein and cDNA sequences of human and chimpanzee epididymal antimicrobial peptides, and therapeutic uses thereof.
Applicant: Froelich O, Young LG (2001)
The invention provides protein and cDNA sequences of novel human and chimpanzee antimicrobial peptides (EP2) expressed in the epididymis. The EP2 proteins of the present invention (EP2A-EP2F) are encoded by the epididymis-specific gene EP2, which has two promoters. Promoter A drives the expression of variants EP2A, EP2C, EP2D and EP2F, while promoter B drives the expression of variants EP2B and EP2E. The proteins of the invention have sequence homol. with beta-defensins, and they are shown to inhibit growth of Neisseria, Chlamydia, Pseudomonas, Escherichia, and Candida. EP2 peptides and the nucleic acids encoding them can be administered to an animal, preferably human, having a microbial infection in an amt. effective to treat the microbial infection, or the endogenous prodn. of EP2 peptides can be upregulated to an amt. effective to treat the microbial infection. In particular, the invention is directed toward the treatment of epididymitis.

Patent No.: WO 038349
Beta-defensins for antibiotics.
Applicant: Forssmann WG, Adermann K, Kluver E, Conejo JR, Nehls M, Wattler S (2001)
The invention discloses beta-defensins Z1-RCIGLXHKIGTC-Z2 [X = F, R; Z1, Z2 are equal to or different from one another; Z1 = (un)substituted amino acid residue with at least one addnl. cysteine; Z2 = peptide residue of up to 20 amino acids with at least two immediately adjacent cysteines, (derivatized) carboxyl]. The defensins of the invention can be used as antibiotic medicaments.

Patent No.: WO 030846
Protein and cDNA sequences of novel mouse beta-defensins zamp3 and zamp4.
Applicant: Adler DA, Gao Z, Holloway JL, Presnell SR (2001)
The present invention provides protein and cDNA sequences for newly identified mouse protein zamp3 and zamp4, novel members of the beta-defensin family that are useful in the study or treatment of microbial infections. Novel zamp3 shares sequence homolog to bovine enteric beta-defensin EPA. The zamp3 gene is mapped on mouse chromosome 8. The zamp4 gene is mapped on mouse chromosome 14. The present invention also includes antibodies to the zamp3 and zamp4 proteins. A std. murine Northern blot tissue distribution results show that zamp3 mRNA signal is below the detection sensitivity in normal tissues.

Patent No.: WO 023002
Disease prevention by transfecting human cells with antimicrobial protein-encoding mRNA.
Applicant: Kisich K, Diamond G (2001)
Disclosed is a method for inhibiting the growth of a microorganism by high efficiency transfection of a human host cell with a nucleic acid encoding an antimicrobial agent, such that the host cell expresses the antimicrobial agent effective to inhibit growth of the microorganism.